Rady Children's Hospital San Diego
San Diego, California, 92123, United States
Location status: Recruiting
Location contact
Aaron Besterman, MD, MD
CONTACT
858-576-1700 ext. 221633
Corrine Blucher, BS
CONTACT
8585761700 ext. 221632
NCT Number: NCT05457140
Rady Children's Institute for Genomic Medicine seeks to understand the genomes and immune systems in 15 children and adolescents who are admitted to Rady Children's Hospital Child and Adolescent Psychiatry Service with psychotic symptoms or schizophrenia. Cutting-edge genome and protein sequencing technology will be used to better understand how immunological and genetic assessments may improve our ability to identify the cause of psychosis and impact care. The investigator also hopes to identify new genetic and/or autoimmune causes of psychosis that may inform new treatment for future patients.
Interested in participating?
Request Info7 year–17 year
All sexes
Interventional
Not applicable
San Diego, California, 92123, United States
Location status: Recruiting
Aaron Besterman, MD, MD
CONTACT
858-576-1700 ext. 221633
Corrine Blucher, BS
CONTACT
8585761700 ext. 221632
Schizophrenia is a severe mental illness that often starts in late adolescence or early adulthood where individuals experience changes in how they perceive and interact with the world around them (psychosis). These extreme changes in how one perceives and interacts with the world can cause great distress and have a very negative impact on one's life. In most cases, the cause of schizophrenia or psychosis is unknown. However, in a small subset of people who develop schizophrenia or psychosis, their own immune system creates antibodies that attack the brain, which leads to psychosis (autoimmune psychosis). In another subset of patients, there are specific genetic changes that serve as major risk factors for developing psychosis. Identifying autoimmune and genetic factors associated with psychosis with psychosis can inform diagnosis, treatment and prognosis. However, it is still currently unknown how frequently these autoimmune and genetic factors are present in adolescents presenting to the hospital with their first psychotic episode and whether testing for them impacts care.
The investigator proposes a deep analysis of both genomes and immune systems of 15 children and adolescents who are admitted to Rady Children's Hospital Child and Adolescent Psychiatry Service with new psychotic symptoms or schizophrenia. The investigator plans to use cutting-edge genome and protein sequencing technology to better understand how immunological and genetic assessments may improve our ability to identify the cause of psychosis and impact care. The investigator also hopes to identify new genetic and/or autoimmune causes of psychosis that may inform new treatments for future patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Individual in whom one of the following criteria is met:
OR
Exclusion criteria
Child/Adolescent patients who do not meet any of the inclusion criteria, or those who:
Genomic sequencing results may be used for diagnosis and treatment of participants.
Whole Proteome programmable phage display immunoprecipitation sequencing will be used to diagnose known and novel autoantibodies.
Time frame: 2 years
Diagnostic rate of brain reactive autoantibodies via genomic and whole human proteome programmable phage display immunoprecipitation sequencing (PhIP-Seq)
Contact information is provided by the study sponsor or research team.
Aaron Besterman, MD
CONTACT
858-576-1700 ext. 221633
Corrine Blucher, BS
CONTACT
858-576-1700 ext. 221632
Rady Pediatric Genomics & Systems Medicine Institute
Other
Multiomic Diagnostics in Child and Adolescent Psychosis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05617898
Anhedonia, Mental Disorders
Birmingham, Alabama, United States
View Trial DetailsNCT07470437
Behavior, Mental Disorders
Preston, Lancashire, United Kingdom
View Trial DetailsNCT07263022
Bipolar Disorder With Psychotic Features, Cognition
Minneapolis, Minnesota, United States
View Trial DetailsNCT07716969
Mental Disorders, Psychosis
Copenhagen, Denmark
View Trial Details